Maxim Group reiterated coverage on Cassava Sciences with a new price target
$SAVA
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group reiterated coverage of Cassava Sciences with a rating of Buy and set a new price target of $190.00 from $80.00 previously